Cadrenal Therape Stock Price, News & Analysis

Cadrenal Therapeutics (CVKD) provided its 2024 year-end update, highlighting progress in developing tecarfarin for left ventricular assist device (LVAD) patients and rare cardiovascular conditions. Key achievements include: FDA Orphan Drug Designation for tecarfarin in LVAD patients, successful fundraising of $9.8 million bringing cash balance to $11.3 million, and completion of manufacturing readiness for the upcoming Phase 3 trial.

The company held a Type B meeting with the FDA regarding the pivotal Phase 3 trial protocol, with updates expected in Q1 2025. Tecarfarin aims to provide a superior alternative to warfarin for chronic anticoagulation in LVAD patients. The company also joined the Anticoagulation Forum and was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook.

Cadrenal Therapeutics (CVKD) announces its participation in three key events during the 43rd Annual J.P. Morgan Healthcare Conference Week in January 2025. The company will present updates on tecarfarin, their novel oral vitamin K antagonist designed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.

CEO Quang X. Pham will participate in the Longwood Healthcare Leaders discussions on January 11-12, attend the Nasdaq Opening Bell Ceremony on January 13, and along with COO Jeff Cole, will conduct one-on-one investor meetings during the conference. The company plans to outline its Phase 3 clinical development plan, regulatory approval strategy, and three-year vision.

Cadrenal Therapeutics (Nasdaq: CVKD) has been named '2024 Anticoagulation Therapy Company of the Year' by Pharma Tech Outlook for its development of tecarfarin, a new vitamin K antagonist anticoagulant. The company is developing tecarfarin as a potentially safer alternative to warfarin for patients with implanted left ventricular assist devices (LVADs) and rare cardiovascular conditions. Unlike warfarin, tecarfarin uses a unique metabolic pathway less affected by drug-drug interactions and kidney impairment. The drug has received orphan drug and fast-track designations, positioning it to address unmet needs in chronic anticoagulation treatment.

Cadrenal Therapeutics (CVKD) highlighted a presentation at the EACTS Medical Congress featuring tecarfarin data and their proposed clinical trial protocol. The presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), focused on evaluating tecarfarin versus warfarin in patients with Abbott HeartMate3 left ventricular assist device. Dr. Mandeep R. Mehra presented data showing the relationship between bleeding rates and time in therapeutic range for HM3 patients, and evidence of tecarfarin's potential to improve TTR. The presentation also highlighted that end-stage kidney disease doesn't alter tecarfarin exposure, unlike warfarin, which is significant as many LVAD patients have kidney impairment.

Cadrenal Therapeutics (NASDAQ: CVKD) provided a Q3 2024 corporate update highlighting progress in developing tecarfarin, a new vitamin K antagonist for anticoagulation. Key developments include FDA discussions regarding Phase 3 trial protocol for LVAD patients, advancement of Abbott collaboration talks, and joining the Anticoagulation Forum's Corporate Council. The company successfully raised $9.8 million through ATM and warrant exercises, increasing cash balance to $11.3 million. Q3 operating expenses were $2.5 million, with $2.2 million used in operating activities. Tecarfarin is positioned as the only anticoagulant in development for patients with implanted cardiac devices and rare cardiovascular conditions.

Cadrenal Therapeutics (CVKD) announced the exercise of warrants to purchase 285,715 shares of common stock at a reduced price of $16.50 per share, down from the original $26.25. The company will issue new unregistered Series A-1 and A-2 warrants, each for 285,715 shares at $16.50 per share. The gross proceeds are expected to be $4.7 million, which will be used for pivotal Phase 3 trial and partnering activities. The new warrants will have terms of five years and eighteen months respectively, and the company will file a registration statement for the resale of shares.

Cadrenal Therapeutics (NASDAQ: CVKD) has successfully raised $5.1 million through an at-the-market (ATM) facility by selling 391,243 shares of common stock at an average price of $13.15 per share. Following this transaction, the company now has 1,496,771 shares outstanding and a cash balance of approximately $7.4 million. The funds will support the development of tecarfarin, a new vitamin K antagonist for patients with implanted cardiac devices or rare cardiovascular conditions, including preparation for a pivotal Phase 3 trial and ongoing partnering activities.

Cadrenal Therapeutics (Nasdaq: CVKD) has joined the Corporate Council of the Anticoagulation Forum (AC Forum), the largest professional organization of anticoagulation specialists. The company, which is developing tecarfarin, a new vitamin K antagonist for patients with implanted cardiac devices or rare cardiovascular conditions, will collaborate with AC Forum's 15,000 healthcare professional members to advance anticoagulation care quality and safety. This partnership aims to address unmet clinical needs, share research, and promote educational initiatives for improving patient outcomes on anticoagulants.

Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, announced its participation in the Lytham Partners Fall 2024 Investor Conference. The virtual event will take place on Tuesday, October 1, 2024.

Key points:

• Cadrenal will deliver a webcast presentation at 2:00 pm ET
• The presentation will be accessible via the conference home page or a direct link
• Company management will participate in virtual one-on-one meetings with investors
• Investors can arrange meetings through Lytham Partners or by registering for the event

Tecarfarin is described as a new vitamin K antagonist designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.